Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study

被引：6
作者：
Loganadan, Navin Kumar [1 ]
Huri, Hasniza Zaman [1 ,2 ]
Vethakkan, Shireene Ratna [3 ]
Hussein, Zanariah [4 ]
机构：
[1] Univ Malaya, Fac Pharm, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Clin Invest Ctr, 5th Floor,East Tower, Kuala Lumpur 59100, Malaysia
[3] Univ Malaya, Div Endocrinol, Dept Med, Fac Med, Kuala Lumpur 50603, Malaysia
[4] Putrajaya Hosp, Dept Med, Precinct 7, Putrajaya 62250, Malaysia
来源：
PHARMACOGENOMICS | 2020年 / 21卷 / 09期
关键词：
ABCC8 gene polymorphism; insulin resistance; risk predictors; secondary failure; sulfonylurea; THERAPEUTIC RESPONSE; INSULIN; GLUCOSE; VARIANT; RISK; COMPLICATIONS; POLYMORPHISMS; MECHANISMS; GLICLAZIDE; APOPTOSIS;
D O I：
10.2217/pgs-2019-0171
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Due to several limitations in the study designs of sulfonylurea pharmacogenomics studies, we investigated the clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients. Materials & methods: Patients receiving the maximum sulfonylurea and metformin doses for >1 year were enrolled. Secondary sulfonylurea failure was defined as HbA1c >7.0% (>53 mmol/mol) after a 12-month follow-up. Results: By multivariate analysis, increased insulin resistance (HOMA2-IR), baseline HbA1c >7.0%, residing in eastern Peninsular Malaysia, and the CC genotype of rs757110 ABCC8 gene polymorphism were independent predictors of secondary sulfonylurea failure (p < 0.05) while sulfonylurea-induced hypoglycemia was protective against such failure (p < 0.05). Conclusion: Sulfonylurea does not benefit patients with an increased risk of secondary sulfonylurea failure.
引用
收藏
页码：587 / 600
页数：14
相关论文
共 46 条
[1]   Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration [J].
Abu Hassan, Hasliza ;
Tohid, Hizlinda ;
Amin, Rahmah Mohd ;
Bidin, Mohamed Badrulnizam Long ;
Muthupalaniappen, Leelavathi ;
Omar, Khairani .
BMC FAMILY PRACTICE, 2013, 14
[2]  
Al-Qazaz H, 2010, PRACT DIABETES INT, V27, P238
[3]   Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020 [J].
不详 .
DIABETES CARE, 2020, 43 :S98-S110
[4]   The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel [J].
Chistiakov, Dimitry A. ;
Potapov, V. A. ;
Smetanina, S. A. ;
Bel'chikova, L. N. ;
Suplotova, L. A. ;
Nosikov, V. V. .
ACTA DIABETOLOGICA, 2011, 48 (03) :227-235
[5]   IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045 [J].
Cho, N. H. ;
Shaw, J. E. ;
Karuranga, S. ;
Huang, Y. ;
Fernandes, J. D. da Rocha ;
Ohlrogge, A. W. ;
Malanda, B. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 138 :271-281
[6]  
Diabetes Trials Unit, 2013, HOMA CALC
[7]   Glucose and tolbutamide induce apoptosis in pancreatic β-cells -: A process dependent on intracellular Ca2+ concentration [J].
Efanova, IB ;
Zaitsev, SV ;
Zhivotovsky, B ;
Köhler, M ;
Efendic, S ;
Orrenius, S ;
Berggren, PO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (50) :33501-33507
[8]   Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in Egyptian patients with type 2 diabetes [J].
El-sisi, Alaa E. ;
Hegazy, Sahar K. ;
Metwally, Shereen S. ;
Wafa, Alaa M. ;
Dawood, Naglaa A. .
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2011, 2 (04) :155-164
[9]   Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients [J].
Feng, Yan ;
Mao, Guangyun ;
Ren, Xiaowei ;
Xing, Houxun ;
Tang, Genfu ;
Li, Qiang ;
Li, Xuiqi ;
Sun, Lirong ;
Yang, Jinqui ;
Ma, Weiqing ;
Wang, Xiaobin ;
Xu, Xiping .
DIABETES CARE, 2008, 31 (10) :1939-1944
[10]  
Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
12345